“AML is usually not eradicated with traditional, conventional chemotherapy,” says Dan Pollyea, MD, MS, Clinical Director of Leukemia Services and associate professor in the Division of Hematology, “and is a source of relapse when it occurs, which historically is pretty much always with this disease.”
Through a close and collaborative partnership with Craig Jordan, PhD, Chief of the Division of Hematology, Pollyea and their respective teams have spearheaded an interconnected clinical and research approach to not only understand AML, but unravel how to treat it by exploiting the weaknesses in the leukemia stem cell population.
In the video below – produced as part of the “This Is Breakthrough” series documenting the remarkable talent and innovations taking place on the Anschutz Medical Campus – see Pollyea explain his research and clinical philosophy, and the remarkable positive impacts their breakthroughs are having on his patients.
